SCHEMBL333666

SCHEMBL333666

CCOC(=O)Cc1c(C(=O)OCC)c2cc(O)ccc2n1-c1cccc(Cl)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 1/20 0.64
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
ALOX5 P09917 10/20 0.59
TSHR P16473 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
LMNA P02545 3/20 0.50
KDM4E B2RXH2 3/20 0.50
GAA P10253 2/20 0.50
HPGD P15428 2/20 0.50
ALDH1A1 P00352 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MAPT P10636 2/20 0.49
PKM P14618 2/20 0.49
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
ALOX15 P16050 1/20 0.46
CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL334043 0.90 PTGES (0.61) PTGESMEN1KMT2AALOX5TSHR
SCHEMBL333454 0.89 MEN1 (0.74) PTGESMEN1KMT2AALOX5TSHR
SCHEMBL333866 0.89 MEN1 (0.59) PTGESMEN1KMT2AALOX5TSHR
SCHEMBL333920 0.84 KMT2A (0.57) PTGESMEN1KMT2AALOX5TSHR
SCHEMBL333979 0.84 PTGES (0.55) PTGESMEN1KMT2ATSHRNPSR1
SCHEMBL334026 0.82 PTGES (0.46) PTGESMEN1KMT2AALOX5HPGD
SCHEMBL333699 0.82 MAPT (0.61) PTGESMEN1KMT2AALOX5TSHR
SCHEMBL333861 0.82 PTGES (0.46) PTGESMEN1KMT2AALOX5KDM4E
SCHEMBL333996 0.82 MEN1 (0.55) PTGESMEN1KMT2AALOX5TSHR
SCHEMBL333953 0.82 KMT2A (0.60) PTGESMEN1KMT2AALOX5TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097623-B2 1-Aryl-or heteroaryl-3-aryl-or heteroarylindole-2-carboxylic acids or esters: e.g., 5-(4-tert-Butylphenyl)-1,3-bis(4-isopropoxyphenyl)-indole-2-carboxylic acid; inhibition of the activity of microsomal prostaglandin E synthase-1, leukotriene C4 and/or 5-lipoxygenase-activating protein; analgesics BIOLIPOX AB (SE) 2012-01-17 US disclosed
EP-1841735-B1 INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2011-03-09 EP disclosed
US-20090076004-A1 Indoles Useful in the Treatment of Inflammation BIOLIPOX AB (SE) 2009-03-19 US disclosed
EP-1841735-A1 INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION Biolipox AB (SE) 2007-10-10 EP disclosed
WO-2006077366-A1 INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2006-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076004-A1 Indoles Useful in the Treatment of Inflammation IDO1, IDO2, AREG PTGES 34/4885MEN1 2066/4885KMT2A 3484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.